NICardipine for Fast Achievement of Systolic BP Targets in ICH
- Sponsor
- Aarhus University Hospital
- Study ID
- NCT07044232
- Phase
- PHASE4
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Intracerebral Haemorrhage
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Nicardipine — COMBINATION_PRODUCTNicardipine infusion based acute blood pressure lowering treatment
- Glyceryl trinitrate — COMBINATION_PRODUCTGlyceryltrinitrate based acute blood pressure lowering treatment
Study Details
Quality improvement study with a quasi-randomized design. The study monitors the effect of a gradually implemented treatment algorithm prioritizing intravenous antihypertensives (e.g., nicardipine) over long-acting nitrate patches. It aims to increase the proportion of patients reaching target systolic BP \<140 mmHg within 1 hour of hospital admission while monitoring safety, clinical outcomes, and healthcare resource utilization.
Key Dates
- Start date
- Oct 1, 2025
- Status verified
- Jun 2025
- Primary completion
- Dec 31, 2025
- Completion
- Dec 31, 2027
Study Design
- Enrollment
- 88 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Nicardipine infusion based acute blood pressure lowering treatment1. Nicardipine : Infusion at 5 mg/hour ( 2.5 mg/hour in renal or hepatic impairment and elderly. Taper after 4-6 hours. 2. Labetalole: Dose: 10-20 mg IV, repeat as needed. 3. Methyldopa: Dose: 250 mg three times daily (max 500 mg four times daily) orally or via feeding tube Acute antihypertensive treatment duration \<72 hours
- Active Comparator: Glyceryl trinitrate patchbased acute blood pressure lowering treatment1. Glyceryltrinitrate : Patch 5 or 10mg/24hour. 2. Labetalole: Dose: 10-20 mg IV, repeat as needed. 3. Nimotope: Dose: 30 or 60mg x 6 orally or via feeding tube Acute antihypertensive treatment duration \<72 hours
Primary Outcome Measure
Target blood pressure < 140 mmHg 1 hour after admission. [ Time Frame: 1 hour after stroke center admission ]
Central Contacts
- Rolf Blauenfeldt, MD, PhD+4520774053
- Claus Z Simonsen, MD, PhD
Related Studies
- The EBC Recovery StudyRecruiting · University of Miami · Miami, Florida
- International Care Bundle Evaluation in Cerebral Hemorrhage ResearchPHASE4 · Recruiting · Region Skane · Oklahoma City, Oklahoma
- Psychedelic Healing: Adjunct Therapy Harnessing Opened MalleabilityPHASE1 · Recruiting · Johns Hopkins University · Baltimore, Maryland
- Testing the Effectiveness of a Novel Intervention to Improve Medication Adherence in Stroke SurvivorsRecruiting · Massachusetts General Hospital · Boston, Massachusetts